PND37 The Cost-Effectiveness of Buccolam® (Licensed Oromucosal Midazolam) for the Treatment of Acute Epileptic Seizures in the UK; a Hybrid Model Solution
Nov 1, 2012, 00:00 AM
10.1016/j.jval.2012.08.1961
https://www.valueinhealthjournal.com/article/S1098-3015(12)03674-1/fulltext
Section Title :
Neurological Disorders
Section Order :
1449
First Page :
A552
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03674-1&doi=10.1016/j.jval.2012.08.1961